MPLT
Income statement / Annual
Last year (2024), MapLight Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, MapLight Therapeutics, Inc.'s net income was -$77.58 M.
See MapLight Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$701.00 K
|
$556.00 K
|
$574.00 K
|
| Gross Profit |
-$701.00 K
|
-$556.00 K
|
-$574.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$67.82 M
|
$49.12 M
|
$26.57 M
|
| General & Administrative Expenses |
$14.42 M
|
$7.61 M
|
$4.10 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.42 M
|
$7.61 M
|
$4.10 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$82.25 M
|
$56.73 M
|
$30.67 M
|
| Cost And Expenses |
$82.95 M
|
$57.28 M
|
$31.25 M
|
| Interest Income |
$4.50 M
|
$1.10 M
|
$429.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$701.00 K
|
$556.00 K
|
$574.00 K
|
| EBITDA |
-$76.88 M |
-$55.15 M |
-$29.44 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.37 M
|
$1.57 M
|
$1.23 M
|
| Income Before Tax |
-$77.58 M
|
-$55.71 M
|
-$30.02 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$77.58 M
|
-$55.71 M
|
-$30.02 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.87 |
-1.34 |
-0.72 |
| EPS Diluted |
-1.87 |
-1.34 |
-0.72 |
| Weighted Average Shares Out |
$41.43 M
|
$41.43 M
|
$41.43 M
|
| Weighted Average Shares Out Diluted |
$41.43 M
|
$41.43 M
|
$41.43 M
|
| Link |
|
|
|
